Thus, these vaccines demonstrated the ability to elicit AR-specific and AR-V7-specific T cells responses in mice, which varied based on their genetic background and MHC-I repertoire, suggesting their potential utility against prostate cancer. This evidence concerns the gene AR and prostate carcinoma.